Richmond Brothers, Inc. Picked Rockwell Medical Inc. (NASDAQ:RMTI) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Rockwell Medical Inc. (NASDAQ:RMTI), reported that Richmond Brothers, Inc. has picked up 5,172,452 of common stock as of 2017-03-23.
The acquisition brings the aggregate amount owned by Richmond Brothers, Inc. to a total of 5,172,452 representing a 10.0% stake in the company.
For those not familiar with the company, Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.
A glance at Rockwell Medical Inc. (NASDAQ:RMTI)’s key stats reveals a current market capitalization of 315.74 Million based on 51.53 Million shares outstanding and a price at last close of $5.88 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-03-22, Richmond picked up 21,076 at a purchase price of $5.94. This brings their total holding to 29,802 as of the date of the filing.
On the sell side, the most recent transaction saw Holt unload 3,200 shares at a sale price of $5.97. This brings their total holding to 12,630.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Rockwell Medical Inc. (NASDAQ:RMTI) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Bb Biotech Ag Picked Radius Health Inc. (NASDAQ:RDUS) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Radius Health Inc. (NASDAQ:RDUS) reported that Bb Biotech Ag has picked up 4,718,922 of common stock as of 2017-03-22.
The acquisition brings the aggregate amount owned by Bb Biotech Ag to a total of 4,718,922 representing a 10.9% stake in the company.
For those not familiar with the company, Radius Health, Inc. is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.
A glance at Radius Health Inc. (NASDAQ:RDUS)’s key stats reveals a current market capitalization of 1.48 Billion based on 43.19 Million shares outstanding and a price at last close of $36.87 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-03-21, Biotech picked up 50,000 at a purchase price of $35.83. This brings their total holding to 4,540,399 as of the date of the filing.
On the sell side, the most recent transaction saw Ward unload 25,000 shares at a sale price of $62.77. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Radius Health Inc. (NASDAQ:RDUS) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Sofinnova Venture Partners Picked Versartis Inc. (NASDAQ:VSAR) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Versartis Inc. (NASDAQ:VSAR) reported that Sofinnova Venture Partners Viii, L.p. has picked up 1,658,865 of common stock as of 2017-03-17.
The acquisition brings the aggregate amount owned by Sofinnova Venture Partners Viii, L.p. to a total of 1,658,865 representing a 4.7% stake in the company.
For those not familiar with the company, Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology. The Company’s VRS-317 combines the rhGH amino acid sequence utilized in approved rhGH products with a half-life extension technology, XTEN, to enable less frequent administration. The XTEN technology consists of hydrophilic amino acids added at the genetic level as part of the manufacturing process. The Company’s XTEN is a recombinant polypeptide designed to extend the in vivo half-life of peptides and proteins in a tunable manner. The XTEN sequence consists of hydrophilic amino acids and possesses various additional properties, which are used for the development of protein pharmaceuticals.
A glance at Versartis Inc. (NASDAQ:VSAR)’s key stats reveals a current market capitalization of 646.60 Million based on 35.05 Million shares outstanding and a price at last close of $18.98 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-02-13, Perceptive picked up 59,133 at a purchase price of $15.51. This brings their total holding to 4,229,563 as of the date of the filing.
On the sell side, the most recent transaction saw Malik unload 103,122 shares at a sale price of $19.08. This brings their total holding to 2,105,228.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Versartis Inc. (NASDAQ:VSAR) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Cpmg Inc. Picked Up Reata Pharmaceuticals Inc. (NASDAQ:RETA) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported that Cpmg Inc. has picked up 3,161,180 of common stock as of 2017-03-06.
The acquisition brings the aggregate amount owned by Cpmg Inc. to a total of 3,161,180 representing a 20.9% stake in the company.
For those not familiar with the company, Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company’s lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich’s ataxia, mitochondrial myopathies and metastatic melanoma.
A glance at Reata Pharmaceuticals Inc. (NASDAQ:RETA)’s key stats reveals a current market capitalization of 659.60 million based on 22.34 Million shares outstanding and a price at last close of $28.14 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-30, Traweek picked up 9,392 at a purchase price of $21.72. This brings their total holding to 1,926,034 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Reata Pharmaceuticals Inc. (NASDAQ:RETA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
1globe Capital Llc. Picked Up Exelixis Inc. (NASDAQ:EXEL) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Exelixis Inc. (NASDAQ:EXEL) reported that 1globe Capital Llc. has picked up 5,437,285 of common stock as of 2017-02-15.
The acquisition brings the aggregate amount owned by 1globe Capital Llc. to a total of 5,437,285 representing a 1.9% stake in the company.
For those not familiar with the company, Exelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins.
A glance at Exelixis Inc. (NASDAQ:EXEL)’s key stats reveals a current market capitalization of 6.08 billion based on 286.46 million shares outstanding and a price at last close of $22.02 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-05-11, Willsey picked up 20,000 at a purchase price of $4.95. This brings their total holding to 568,273 as of the date of the filing.
On the sell side, the most recent transaction saw Lamb unload 70,000 shares at a sale price of $18.65. This brings their total holding to 73,600.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Exelixis Inc. (NASDAQ:EXEL) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.